Sorry, you need to enable JavaScript to visit this website.

Support & Resources | RYBREVANT® (amivantamab-vmjw) HCP

NOW APPROVED FOR FIRST-LINE THERAPY!

Resources for HCPs

divider-support-mob
hcp_tilemb

Hear From an Expert

A leader in oncology weighs in on RYBREVANT®, a first-of-its-kind treatment option for patients with mNSCLC with EGFR exon 20 insertion mutations

hcp_tilemb

RYBREVANT® NCCN Guidelines Flashcard

See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendation for RYBREVANT®

hcp_tilemb

RYBREVANT® Dosing and Administration Guide

Comprehensive dosing, dose modification, preparation, and administration for RYBREVANT®

hcp_tilemb

RYBREVANT® Adverse Reactions Management Guide

A detailed look at potential adverse reactions that can occur during treatment with RYBREVANT®

hcp_tilemb

RYBREVANT® Rash Management Guide

A step-by-step guide to help manage dermatologic adverse reactions that patients may experience during treatment

hcp_tilemb

Testing and Treatment for EGFR Exon 20 Insertion Mutation+ mNSCLC

An overview of the NCCN Guidelines® recommendations for the testing and treatment of mNSCLC with EGFR exon 20 insertion mutations

hcp_tilemb

Mechanism of Disease (MOD) Video

Learn what makes most EGFR exon 20 insertion mutations different

hcp_tilemb

Janssen CarePath

Janssen CarePath is your one source for access, affordability, and treatment support for your patients

hcp_tilemb

Reference Lab Fact Sheet

Biomarker testing guidelines and a list of liquid and tissue NGS test providers

Resources for Patients

divider-support-mob
patmb_img

RYBREVANT® Prospective Patient Brochure

Getting patients started on their journey with RYBREVANT®

patmb_img

RYBREVANT® Patient Starter Kit Brochure

Helpful information for patients to manage their treatment

patmb_img

RYBREVANT® Patient Starter Kit Advocacy Flashcard

Organizations in the mNSCLC community that provide support during treatment

patmb_img

RYBREVANT® Patient Starter Kit Infusion Schedule Flashcard

An overview to help patients understand and prepare for their infusions during treatment

patmb_img

RYBREVANT® Patient Starter Kit Treatment Journal

A tool to help patients stay organized, prepare, and reflect during their treatment on RYBREVANT®

patmb_img

Janssen CarePath

Information on insurance coverage, out-of-pocket costs, and treatment support

patmb_img

Janssen CarePath Savings Program for RYBREVANT®

Eligible commercially insured patients can save on their out-of-pocket medication costs for RYBREVANT®

Resources for Access & Affordability

divider-support-mob
aaimg_mb

RYBREVANT® Medicare Payment Policy Flashcard

Important information regarding Medicare's payment policy for RYBREVANT®

aaimg_mb

Coding & Billing Flashcard

An explanation for office staff about insurance codes and billing

aaimg_mb

Specialty Distributor Flashcard

How to order RYBREVANT® for your patients

aaimg_mb

Access and Reimbursement Guide

A helpful guide to navigating access for RYBREVANT®

aaimg_mb

Sample Letter of Medical Necessity (LMN)

An editable LMN template to use either with an initial claim or when requesting reconsideration for a denied claim

aaimg_mb

Sample Exception Letter

A template exception letter to use when requesting an exception for RYBREVANT®

Patient Support

divider-support-mob

Lung Cancer Communities and Organizations

EGFR Resisters

The EGFR Resisters is a group of people living with and/or personally affected by EGFR-positive lung cancer.
egfrcancer.org

Exon 20 Group

Patients and their families are welcome to join the Exon 20 Group. Membership is free of charge.
exon20group.org
1-602-618-0183

The GO2 Foundation for Lung Cancer

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.
go2foundation.org
1-800-298-2436

Lung Cancer Foundation of America (LCFA)

LCFA’s mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.
lcfamerica.org

LUNGevity

LUNGevity is the largest national lung cancer-focused nonprofit. They are committed to changing the outcomes for people with lung cancer through research, education, and support.
lungevity.org
1-844-360-5864

These groups and foundations are not affiliated with Janssen Biotech, Inc. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by Janssen Biotech, Inc., or any groups or foundations referenced herein.

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF)

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization. JJPAF gives eligible patients free prescription medicines donated by Johnson & Johnson companies. Patients may be eligible if they don’t have insurance.

Do you have patients who may need help? They can see if they are eligible and get an application at JJPAF.org or call 800-652-6227 (Monday through Friday, 8:00 AM to 8:00 PM ET).

Explore

cnt-divider

safetylogo

Safety

Review the safety profile
of RYBREVANT®.

Learn more

dosinglogo

Dosing Guidelines

See the recommended dosage,
preparation and administration,
and dose modification information.

Learn more

efficacylogo

Efficacy

Explore the results from the
CHRYSALIS trial.

Learn more

register

Register for Updates

Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.